Product/Composition:- | Captopril tablet |
---|---|
Strength:- | 25 mg, 50 mg, 100 mg |
Form:- | Tablets |
Reference Brands:- | Capoten(US) |
MOQ | As per the manufacturer batch size |
Get Quote Send Enquiry on WhatsApp |
Captopril is an ACE inhibitor that blocks the conversion of angiotensin I to angiotensin II, reducing vasoconstriction and lowering blood pressure. It improves cardiovascular function, decreases heart failure symptoms, and prevents strokes and heart attacks. Benefits include blood pressure control, improved cardiac output, and long-term cardiovascular health.
Captopril tablets, marketed as Capoten, are approved in the US by the FDA and in the EU via EMA for hypertension and heart failure. Regulatory approval requires a comprehensive dossier including clinical efficacy, safety data, manufacturing standards, and pharmacovigilance plans. In the US, the FDA reviews detailed clinical trial and quality information, while the EMA ensures compliance with regional safety and manufacturing standards. For guidance on dossier preparation, regulatory pathways, and market access, visit PharmaTradz. Proper adherence to regional requirements supports timely approval, safe use, and global availability of captopril tablets, assisting healthcare providers in managing cardiovascular conditions worldwide efficiently and effectively.